Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
Nat Commun. 2016 Nov 2;7:13467. doi: 10.1038/ncomms13467. NO ABSTRACT PMID:27804975 | PMC:PMC5097131 | DOI:10.1038/ncomms13467
Our research is focused on the study of the implication of intracellular signaling cascades driving to pathological situations in cancer and vascular diseases.
The molecular signaling cascades that take place inside the cells are essential to respond to changes in their environment or to alter their homeostasis, for example, at the level of cell proliferation, movement, growth or metabolism. Understanding how these mechanisms of signal transduction work can explain how biological processes are controlled in a normal physiological context, but also, the alterations that take place in many pathologies. Our group investigates this in two pathological contexts: The first is ovarian epithelial cancer, where we study the pathways involved in metastasis and the mechanisms of resistance to therapies. A second context is a rare vascular disease, HHTs, in which, in collaboration with the group led by Toni Riera (Hospital de Bellvitge), we study which signaling pathways are altered in patients with mutations that cause this disease, and how treat them with new drugs.
Publications
Nat Commun. 2016 Nov 2;7:13467. doi: 10.1038/ncomms13467. NO ABSTRACT PMID:27804975 | PMC:PMC5097131 | DOI:10.1038/ncomms13467
Oncotarget. 2016 Jul 26;7(30):48265-48279. doi: 10.18632/oncotarget.10199. ABSTRACT Current treatments for pancreatic ductal adenocarcinoma (PDA) are ineffective, making this the 4th leading cause of cancer deaths. Sunitinib is a broad-spectrum inhibitor of tyrosine kinase receptors mostly known for its anti-angiogenic effects. We tested the therapeutic effects of sunitinib in pancreatic cancer using the Ela-myc transgenic mouse […]
Int J Cancer. 2016 Oct 15;139(8):1894-903. doi: 10.1002/ijc.30233. Epub 2016 Jun 25. ABSTRACT In a search for new therapeutic targets for treating epithelial ovarian cancer, we analyzed the Transforming Growth Factor Beta (TGFβ) signaling pathway in these tumors. Using a TMA with patient samples we found high Smad2 phosphorylation in ovarian cancer tumoral cells, independently […]
Clin Cancer Res. 2016 Dec 1;22(23):5805-5817. doi: 10.1158/1078-0432.CCR-15-3051. Epub 2016 May 25. ABSTRACT PURPOSE: Mutations in the PI3K pathway occur in 16% of patients with pancreatic neuroendocrine tumors (PanNETs), which suggests that these tumors are an exciting setting for PI3K/AKT/mTOR pharmacologic intervention. Everolimus, an mTOR inhibitor, is being used to treat patients with advanced PanNETs. […]
Cell Rep. 2016 May 10;15(6):1134-43. doi: 10.1016/j.celrep.2016.04.015. Epub 2016 Apr 28. ABSTRACT Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tumor cells distal and proximal […]
Research Projects
– Ref: PID2020-117815RB-I00 Title: El perfil metabólico como una oportunidad terapéutica en el cáncer epitelial de ovario. implicaciones en metástasis y resistencia a los tratamientos. DGICYT, MINECO. 2021-2024. 217.800 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.
– Ref: SAF2017-85869-R Title: Mecanismos de señalización y control metabólico implicados en la diseminación y quimioresistencia en cáncer epitelial de ovario. DGICYT, MINECO. 2018-2020. 181.500 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.
Collaborations
Peter B. Vermeulen, University of Antwerp and GZA Hospitals, Belgium
Artur Mezheyeuski, VHIO, Barcelona
Pnina Brodt, Mc Gill University, Montreal, Canada
and Liver Metastases Research Network members


Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

